Targets to treat androgen excess in polycystic ovary syndrome

  title={Targets to treat androgen excess in polycystic ovary syndrome},
  author={Manuel Luque‐Ram{\'i}rez and H{\'e}ctor Francisco Escobar-Morreale},
  journal={Expert Opinion on Therapeutic Targets},
  pages={1545 - 1560}
Introduction: The polycystic ovary syndrome (PCOS) is a common androgen disorder in reproductive-aged women. Excessive biosynthesis and secretion of androgens by steroidogenic tissues is its central pathogenetic mechanism. Areas covered: The authors review the potential targets and new drugs to treat androgen excess in PCOS. Besides our lab’s experience, a systematic search (MEDLINE, Cochrane library,, EU Clinical Trials Register and hand-searching) regarding observational… 

Treatment strategies for women with polycystic ovary syndrome

  • Peipei JinYongyong Xie
  • Medicine
    Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • 2018
Because current treatments cannot cure PCOS, lifelong administration is still the mainstream method of management; however, the optimal treatment plan needs further research and exploration.

A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy

There is no solid evidence supporting that the use of combined oral contraceptives in women with PCOS increases the risk of cardiovascular or thromboembolic events compared with the general population.

Diagnosis, Pathogenesis and Management of Polycystic Ovary Syndrome

Many therapies are available for improving reproductive and metabolic abnormalities in PCOS patients, in which lifestyle modification and insulin-sensitizing agents are more effective management strategies.

Polycystic ovary syndrome in adult women

Combined oral contraceptives and/or antiandrogens versus insulin sensitizers for polycystic ovary syndrome: a systematic review and meta-analysis

The global quality of evidence was very low when addressing the impact of the treatments explored on prevalence of hypertension and lipid profiles, low in the case of hirsutism, BMI and blood pressure values, and high for endometrial protection and glucose tolerance.

Pharmacotherapeutic management of comorbid polycystic ovary syndrome and diabetes

ABSTRACT Introduction: Polycystic ovary syndrome (PCOS) is a common endocrine disorder in premenopausal women. Insulin resistance and glucose intolerance are very prevalent metabolic complications in

Should we individualize lipid profiling in women with polycystic ovary syndrome?

Lipid profiling rarely changes the clinical care of low risk PCOS patients before the age of 35, especially in the normal-weight women, and can only be generalized to countries with low cardiovascular mortality rates.

Progranulin and tumor necrosis factor-alpha in lean polycystic ovary syndrome patients

PGRN level increase in lean PCOS patients may be due to inhibiting the inflammatory effects of TNF-α, and to observe the PGRN and T NF-α connection in obesity, further study is needed in obese PCos patients and obese control groups.

Steroid Hormone Profiling in Hyperandrogenism and Non-hyperandrogenism Women with Polycystic Ovary Syndrome

The HA- PCOS and the NA-PCOS women showed different steroid profiles, and the different enzyme activities in steroidogenic pathway may be the main reason for the difference.

QSAR Analysis of a Series of Hydantoin‐based Androgen Receptor Modulators and Corresponding Binding Affinities

The derived model can be used to predict the binding abilities of unknown chemicals and may help to design novel molecules with better AR affinity activity.



Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.

Drugs commonly used to treat PCOS appear to be associated with very low risk of severe adverse effects although data are extrapolated from other populations.

Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.

It is the view of the AES Task Force on the Phenotype of PCOS that there should be acceptance of the original 1990 National Institutes of Health criteria with some modifications, taking into consideration the concerns expressed in the proceedings of the 2003 Rotterdam conference.

Lifestyle changes in women with polycystic ovary syndrome.

Lifestyle intervention improves body composition, hyperandrogenism (high male hormones and clinical effects) and insulin resistance in women with PCOS, and provided benefits when compared to minimal treatment for secondary reproductive, anthropometric and reproductive outcomes.

Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis.

The available evidence suggests that LSM reduces fasting blood glucose and insulin levels in women with PCOS and Metformin has similar effects, and translation of these short-term effects to patient-important outcomes, beyond diabetes prevention, remains uncertain.

Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline

Evaluation of women with PCOS should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease.

Hyperandrogenemia Predicts Metabolic Phenotype in Polycystic Ovary Syndrome: The Utility of Serum Androstenedione

Simultaneous measurement of serum T and A represents a useful tool for predicting metabolic risk in PCOS women and HA levels are a sensitive indicator of PCOS-related androgen excess.

Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications.

Polycystic ovary syndrome (PCOS) is now recognized as an important metabolic as well as reproductive disorder conferring substantially increased risk for type 2 diabetes. Affected women have marked

Antiandrogenic Contraceptives Increase Serum Adiponectin in Obese Polycystic Ovary Syndrome Patients

The present results might suggest a direct inhibitory effect of androgen excess on adiponectin secretion by adipocytes in obese PCOS women, supporting the hypothesis that androgens excess contributes to adipocyte dysfunction in these women.